• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球心血管风险、COVID-19 严重程度和新冠后综合征:一项临床研究。

Global cardiovascular risk, COVID-19 severity and post-COVID-19 syndrome: a clinical study.

机构信息

Internal and Subintensive Medicine Department, Azienda Ospedaliera delle Marche, Ancona, Italy.

出版信息

Eur Rev Med Pharmacol Sci. 2023 Dec;27(24):12141-12152. doi: 10.26355/eurrev_202312_34812.

DOI:10.26355/eurrev_202312_34812
PMID:38164876
Abstract

OBJECTIVE

Post-COVID-19 is a syndrome defined by signs and symptoms present until 12 weeks after COVID-19, lasting for more than 8 weeks, not explained by an alternative diagnosis. The present study aimed to assess whether the cardiovascular risk (CVR) of patients with COVID-19 correlates with symptoms and changes in respiratory function parameters in post-COVID-19. The association between CVR and the severity of acute disease was also considered.

PATIENTS AND METHODS

Between 21/04/21-01/09/21, we enrolled 1,782 consecutive patients with COVID-19. We divided these subjects into (i) 4 levels, based on the severity of COVID-19 (home care; hospitalized/no oxygen therapy; hospitalized/oxygen therapy; hospitalized/NIV-ICU), (ii) 2 levels, according to CVR calculated with the European Society of Cardiology SCORE tables (low-intermediate risk; high or very high risk). All subjects underwent a 3-month follow-up considering post-COVID-19 symptoms.

RESULTS

In post-COVID-19 patients, high or very-high CVR was associated with (i) increased risk of hospitalization for COVID-19 (p<0.0001), (ii) higher prevalence of severe clinical manifestations and ICU admission (p<0.0001), (iii) development of post-COVID-19 (p<0.0001) and (iv) increased risk of a larger post-COVID-19 burden of disease.

CONCLUSIONS

We found a statistically significant association between CVR, severity of COVID-19, and post-COVID-19 syndrome three months after the end of acute disease.

摘要

目的

新冠后(post-COVID-19)综合征是指在新冠病毒感染后 12 周内持续存在的症状和体征,持续时间超过 8 周,且不能用其他诊断解释。本研究旨在评估新冠患者的心血管风险(CVR)是否与新冠后(post-COVID-19)的症状和呼吸功能参数变化相关。还考虑了 CVR 与急性疾病严重程度之间的关系。

患者和方法

在 2021 年 4 月 21 日至 9 月 1 日期间,我们连续招募了 1782 名新冠患者。我们根据新冠严重程度将这些患者分为(i)4 个等级,分别为:居家治疗;住院但无需吸氧治疗;住院且需要吸氧治疗;住院且需要使用无创通气/重症监护病房治疗。(ii)根据欧洲心脏病学会 SCORE 表计算的 CVR,将这些患者分为 2 个等级,分别为:低-中危风险;高危或极高危风险。所有患者在 3 个月的随访期间都报告了新冠后(post-COVID-19)症状。

结果

在新冠后(post-COVID-19)患者中,高或极高 CVR 与(i)因新冠再次住院的风险增加(p<0.0001),(ii)严重临床表现和 ICU 入院的发生率较高(p<0.0001),(iii)发生新冠后(post-COVID-19)的风险增加(p<0.0001),(iv)新冠后(post-COVID-19)疾病负担增加的风险增加相关。

结论

我们发现 CVR、新冠严重程度和新冠后(post-COVID-19)综合征之间存在统计学显著关联,这种关联在急性疾病结束后 3 个月仍存在。

相似文献

1
Global cardiovascular risk, COVID-19 severity and post-COVID-19 syndrome: a clinical study.全球心血管风险、COVID-19 严重程度和新冠后综合征:一项临床研究。
Eur Rev Med Pharmacol Sci. 2023 Dec;27(24):12141-12152. doi: 10.26355/eurrev_202312_34812.
2
The Relationship between Post-COVID Syndrome and the Burden of Comorbidities Assessed Using the Charlson Comorbidity Index.新冠后综合征与 Charlson 合并症指数评估的合并症负担之间的关系。
Medicina (Kaunas). 2023 Aug 31;59(9):1583. doi: 10.3390/medicina59091583.
3
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
4
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.血管疾病或心血管危险因素与 COVID-19 患者管理指南:来自血管外科学-欧洲独立血管学基金会/血管医学的立场文件。
Thromb Haemost. 2020 Dec;120(12):1597-1628. doi: 10.1055/s-0040-1715798. Epub 2020 Sep 13.
5
Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients.急性感染后 6 个月住院和非住院患者的 COVID-19 后症状。
Clin Microbiol Infect. 2021 Oct;27(10):1507-1513. doi: 10.1016/j.cmi.2021.05.033. Epub 2021 Jun 7.
6
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
7
Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.肾素-血管紧张素系统调节与因间质 SARS-CoV2 肺炎住院患者结局的关系:一项队列研究。
Intern Emerg Med. 2022 Aug;17(5):1335-1341. doi: 10.1007/s11739-022-02929-7. Epub 2022 Jan 21.
8
Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved.新冠后综合征:流行病学、诊断标准和涉及的发病机制。
Rev Neurol. 2021 Jun 1;72(11):384-396. doi: 10.33588/rn.7211.2021230.
9
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.随机临床试验评估 COVID-19 住院患者使用恢复期血浆的安全性和疗效(PERUCONPLASMA):一项随机对照试验研究方案的结构化总结。
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
10
Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar.卡塔尔一项回顾性队列研究:COVID-19 患者的消化系统受累及临床结局。
World J Gastroenterol. 2021 Dec 14;27(46):7995-8009. doi: 10.3748/wjg.v27.i46.7995.

引用本文的文献

1
Myocardial involvement in post-COVID-19 condition: a note from the surgical approach.新型冠状病毒肺炎康复后心肌受累情况:手术治疗的要点
Cardiovasc Diagn Ther. 2024 Jun 30;14(3):314-317. doi: 10.21037/cdt-24-182. Epub 2024 Jun 21.